Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Lexicon’s biopharmaceutical operations, financial condition, capital-raising activities and risks associated with its pipeline in heart failure, hypertrophic cardiomyopathy, neuropathic pain, obesity, diabetes and related indications.
Investors can review current reports on Form 8-K, where Lexicon discloses material events such as quarterly financial results, at-the-market equity offering arrangements, Nasdaq listing status updates and key business developments. For example, recent 8-K filings describe an Open Market Sale Agreement with Jefferies LLC, legal opinions related to potential share sales, and communications regarding compliance with Nasdaq’s minimum bid price requirement and transfer to The Nasdaq Capital Market.
In addition to 8-Ks, users can locate Lexicon’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR), which typically contain audited financial statements, management’s discussion and analysis, detailed descriptions of products such as sotagliflozin (INPEFA®), pilavapadin (LX9211) and LX9851, as well as information on licensing agreements with partners like Viatris and Novo Nordisk. Proxy materials and other filings may address executive compensation, governance and shareholder matters.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy reports, helping users quickly understand major changes in revenue sources, R&D priorities, collaboration structures, risk factors and capital structure. Real-time updates from EDGAR ensure that new Lexicon filings, including any Form 4 insider transaction reports, become accessible promptly, while AI-generated overviews make complex regulatory language more approachable for both individual and institutional investors.
Lexicon Pharmaceuticals filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company reported an aggregate market value of voting stock held by non-affiliates of $170.0 million based on a $0.95 closing price as of June 30, 2025, and stated 423,680,611 shares outstanding as of March 4, 2026.
The company is focused on advancing sotagliflozin (commercialized as INPEFA and pursued as ZYNQUISTA), pilavapadin (LX9211), and LX9851. FDA proceedings for ZYNQUISTA include two complete response letters and an ongoing public Notice of Opportunity for Hearing; the company may resubmit its NDA contingent on third-party study data. Lexicon disclosed collaboration agreements with Novo Nordisk, Viatris and Bristol-Myers Squibb and reported $61.1 million in R&D expenses for 2025.
Lexicon Pharmaceuticals is asking stockholders to vote at its April 30, 2026 annual meeting on several key items. The company proposes doubling authorized common shares from 450,000,000 to 900,000,000, which would leave 376,875,534 shares authorized but not issued or reserved after assumed conversions and plan approvals. Stockholders are also asked to approve a new 2026 Equity Incentive Plan increasing the share pool to 90,000,000 and a 2026 Non-Employee Directors’ Equity Incentive Plan with up to 6,000,000 shares. Other proposals include electing three Class II directors, an advisory vote on executive compensation, and ratifying Ernst & Young LLP as independent auditors for the year ending December 31, 2026. Common stockholders of record on March 6, 2026, when 423,680,611 shares were outstanding, are entitled to one vote per share.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on small‑molecule drugs for cardiovascular, metabolic and neuropathic diseases, built on internal target discovery from about 5,000 genes. The company devotes most resources to sotagliflozin, pilavapadin, LX9851 and commercialization of INPEFA.
INPEFA (sotagliflozin) is approved in the U.S. to reduce cardiovascular death and heart‑failure events in adults with heart failure or type 2 diabetes, chronic kidney disease and other cardiovascular risk factors, and is sold mainly through major wholesalers and a mail‑order pharmacy. Sotagliflozin is also in the SONATA‑HCM Phase 3 trial for hypertrophic cardiomyopathy and is being pursued as ZYNQUISTA for type 1 diabetes after FDA complete response letters, with a potential NDA resubmission supported by the STENO1 study.
Pilavapadin has shown evidence of effect in multiple Phase 2 neuropathic pain trials and holds FDA Fast Track designation for diabetic peripheral neuropathic pain, with Phase 3 advancement contingent on third‑party collaboration. LX9851 for obesity is licensed exclusively to Novo Nordisk, which paid a $45 million upfront and a $10 million milestone and may owe up to $950 million in additional milestones plus tiered royalties. Sotagliflozin rights in certain territories are licensed to Viatris, which paid a $25 million upfront and may pay up to $197 million in milestones plus royalties.
Lexicon Pharmaceuticals reported 2025 results showing higher revenue and a sharply reduced loss while advancing its pipeline. Total revenues were $49.8 million in 2025 versus $31.1 million in 2024, largely driven by $45 million of licensing revenue from a Novo Nordisk agreement and $4.6 million of INPEFA net sales.
Net loss narrowed to $50.3 million, or $0.14 per share, from $200.4 million, or $0.63 per share, helped by major cost reductions. Research and development expenses fell to $61.1 million from $84.5 million, and selling, general and administrative expenses dropped to $37.3 million from $143.1 million, reflecting a strategic repositioning and reduced INPEFA marketing.
As of December 31, 2025, cash, investments and restricted cash totaled $125.2 million, and in February 2026 the company added approximately $96.7 million of net equity proceeds plus a $10 million milestone payment from Novo Nordisk. Key programs progressed, including SONATA-HCM Phase 3 enrollment surpassing 50%, planned 2026 NDA resubmission for ZYNQUISTA in type 1 diabetes, and Phase 3 readiness for pilavapadin in diabetic neuropathic pain.
Lexicon Pharmaceuticals senior vice president Wendy McDermott reported multiple equity award transactions involving restricted stock units and common stock. On February 28, 2026, she exercised or converted several blocks of restricted stock units into common shares at a stated price of $0.00 per share, including a tranche of 144,393 restricted stock units that became common stock. Each restricted stock unit represents the right to receive one share of common stock, and the units vest in three equal annual installments each February 28 following the grant year.
On the same date, 68,107 common shares were withheld at $1.47 per share to satisfy tax withholding obligations, a non‑market transaction classified as a tax‑withholding disposition. After these transactions, McDermott continued to hold common stock directly, reflecting equity compensation rather than open‑market trading.
LEXICON PHARMACEUTICALS, INC. senior vice president Rachel Yap Martens reported equity compensation activity involving restricted stock units and common shares. On February 28, 2026, she exercised 67,090 restricted stock units, converting them into 67,090 shares of common stock at a price of $0.00 per share.
In a related tax event on the same date, 35,826 common shares were disposed of at $1.47 per share to satisfy tax withholding obligations, as described in the footnotes. After these transactions, she held 31,264 shares of common stock and 134,180 restricted stock units directly. Each restricted stock unit represents the right to receive one share of common stock and vests in three equal annual installments each February 28 following the grant year.
LEXICON PHARMACEUTICALS, INC. Senior Vice President and Chief Medical Officer Craig B. Granowitz reported multiple equity award transactions involving restricted stock units and common stock on February 28, 2026.
He exercised or converted restricted stock units into common shares in three separate transactions of 35,790, 74,226, and 202,260 restricted stock units, each at a stated price of $0.00 per unit. Each restricted stock unit represents a contingent right to receive one share of common stock, and these units vest in three equal annual installments on February 28 of each of the three years following the year of grant.
Corresponding non-derivative entries show acquisitions of common stock in matching amounts of 35,790, 74,226, and 202,260 shares, reflecting the settlement of those restricted stock units. A separate transaction disposed of 109,098 shares of common stock at $1.47 per share through withholding of a portion of the issued shares by the company to satisfy the reporting person’s tax withholding obligations. After these transactions, the reporting person directly owned 323,430 shares of common stock.
LEXICON PHARMACEUTICALS, INC. senior vice president of Discovery, Suma Gopinathan, reported multiple equity compensation transactions. On February 28, 2026, she acquired common stock through the exercise and conversion of restricted stock units in blocks of 14,000, 20,310 and 65,640 shares, each at a conversion price of $0.0000 per share. A separate transaction disposed of 24,338 shares of common stock at $1.4700 per share to cover tax withholding obligations, leaving her with 150,132 directly held common shares.
LEXICON PHARMACEUTICALS, INC. senior vice president Lisa DeFrancesco reported equity award activity on common stock. On February 28, 2026, she acquired shares through the exercise and conversion of restricted stock units, including 24,674 and 128,190 units, each representing a right to one common share. A separate transaction disposed of 74,572 common shares at $1.47 per share to satisfy tax withholding obligations, leaving her with directly owned common shares as reported in the filing.
LEXICON PHARMACEUTICALS SVP and General Counsel Brian T. Crum reported multiple exercises of restricted stock units into common stock on February 28, 2026. These were non-cash conversions at $0.00 per share, increasing his directly held common shares. The company also withheld 105,019 common shares at $1.47 per share to cover tax obligations related to the equity awards.